131 related articles for article (PubMed ID: 12757189)
1. Validity of injecting drug users' self report of hepatitis A, B, and C.
Schlicting EG; Johnson ME; Brems C; Wells RS; Fisher DG; Reynolds G
Clin Lab Sci; 2003; 16(2):99-106. PubMed ID: 12757189
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis A prevalence among injection drug users.
Wells R; Fisher D; Fenaughty A; Cagle H; Jaffe A
Clin Lab Sci; 2006; 19(1):12-7. PubMed ID: 16617553
[TBL] [Abstract][Full Text] [Related]
3. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
Maher L; Chant K; Jalaludin B; Sargent P
J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
[TBL] [Abstract][Full Text] [Related]
4. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy.
Elefsiniotis IS; Pantazis KD; Ketikoglou ID; Koutsounas SI; Tsianos EV
Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1227-31. PubMed ID: 17033445
[TBL] [Abstract][Full Text] [Related]
5. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
6. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: a review.
Topp L; Day C; Dore GJ; Maher L
Drug Alcohol Rev; 2009 Nov; 28(6):669-75. PubMed ID: 19930022
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor.
Baklan Z; Gorisek JR; Poljak M; Pisec A
Wien Klin Wochenschr; 2004; 116 Suppl 2():5-7. PubMed ID: 15506302
[TBL] [Abstract][Full Text] [Related]
8. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B immunity in a population of drug and alcohol users.
Polizzotto MN; Whelan G
Drug Alcohol Rev; 2007 Jul; 26(4):417-9. PubMed ID: 17564878
[TBL] [Abstract][Full Text] [Related]
10. Poor validity of self-reported hepatitis B virus infection and vaccination status among young drug users.
Kuo I; Mudrick DW; Strathdee SA; Thomas DL; Sherman SG
Clin Infect Dis; 2004 Feb; 38(4):587-90. PubMed ID: 14765355
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
12. [Hepatitis B and C risk factors in Germany--results of the national surveillance].
Walter J; Radun D; Claus H; Hamouda O; Stark K
Gesundheitswesen; 2005 Jul; 67(7):441-7. PubMed ID: 16103966
[TBL] [Abstract][Full Text] [Related]
13. Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney.
Day C; White B; Ross J; Dolan K
Aust N Z J Public Health; 2003 Oct; 27(5):558. PubMed ID: 14651407
[No Abstract] [Full Text] [Related]
14. Seroprevalences and co-infections of HIV, hepatitis C virus and hepatitis B virus in injecting drug users in Quetta, Pakistan.
Achakzai M; Kassi M; Kasi PM
Trop Doct; 2007 Jan; 37(1):43-5. PubMed ID: 17326891
[TBL] [Abstract][Full Text] [Related]
15. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
Vicknasingam B; Narayanan S; Navaratnam V
Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
[TBL] [Abstract][Full Text] [Related]
16. Two simultaneous hepatitis B virus epidemics among injecting drug users and men who have sex with men in Buenos Aires, Argentina: characterization of the first D/A recombinant from the American continent.
Trinks J; Cuestas ML; Tanaka Y; Mathet VL; Minassian ML; Rivero CW; Benetucci JA; Gímenez ED; Segura M; Bobillo MC; Corach D; Ghiringhelli PD; Sánchez DO; Avila MM; Peralta LA; Kurbanov F; Weissenbacher MC; Simmonds P; Mizokami M; Oubiña JR
J Viral Hepat; 2008 Nov; 15(11):827-38. PubMed ID: 18507755
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague].
Wilczek H; Urbánek P
Cas Lek Cesk; 2003; 142(4):240-3. PubMed ID: 12841128
[TBL] [Abstract][Full Text] [Related]
18. Evidence of multiple hepatitis virus infections in autopsied materials of intravenous drug addicts.
Schleicher S; Schieffer M; Jürgens S; Wehner HD; Flehmig B
Ig Sanita Pubbl; 2005; 61(5):435-50. PubMed ID: 17214028
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore.
Winslow M; Subramaniam M; Ng WL; Lee A; Song G; Chan YH
Singapore Med J; 2007 Jun; 48(6):504-8. PubMed ID: 17538746
[TBL] [Abstract][Full Text] [Related]
20. Patterns of drug use and associated harms among rural injecting drug users: comparisons with metropolitan injecting drug users.
Day C; Conroy E; Lowe J; Page J; Dolan K
Aust J Rural Health; 2006 Jun; 14(3):120-5. PubMed ID: 16706881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
